FIELD: medicine.
SUBSTANCE: group of inventions relates to medicine, specifically to oncology, and can be used in the treatment of malignant neoplasms. Methods of the invention include the administration of 17 to 115 % of the recommended daily dose of a combined drug, comprising trifluridine (FTD) and tipiracil hydrochloride (TPI) in a 1:0.5 molar ratio, and from 11 to 100 % of the recommended dose of an antibody selected from the group consisting of bevacizumab, cetuximab and panitumumab, in combination.
EFFECT: use of inventions enables to enhance the antitumour effect due to the synergistic effect of the combination and to reduce adverse effects.
21 cl, 17 dwg, 12 tbl, 3 ex
